239 related articles for article (PubMed ID: 28815933)
1. An α
Kuo YJ; Chen YR; Hsu CC; Peng HC; Huang TF
J Thromb Haemost; 2017 Nov; 15(11):2230-2244. PubMed ID: 28815933
[TBL] [Abstract][Full Text] [Related]
2. Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.
Gao C; Boylan B; Bougie D; Gill JC; Birenbaum J; Newman DK; Aster RH; Newman PJ
J Clin Invest; 2009 Mar; 119(3):504-11. PubMed ID: 19197137
[TBL] [Abstract][Full Text] [Related]
3. A Novel α
Kuo YJ; Chung CH; Pan TY; Chuang WJ; Huang TF
Toxins (Basel); 2019 Dec; 12(1):. PubMed ID: 31877725
[TBL] [Abstract][Full Text] [Related]
4. Improved Antithrombotic Activity and Diminished Bleeding Side Effect of a PEGylated α
Kuo YJ; Chang YT; Chung CH; Chuang WJ; Huang TF
Toxins (Basel); 2020 Jun; 12(7):. PubMed ID: 32605221
[TBL] [Abstract][Full Text] [Related]
5. FcgammaRII mediates platelet aggregation caused by disintegrins and GPIIb/IIIa monoclonal antibody, AP2.
Huang TF; Chang CH; Ho PL; Chung CH
Exp Hematol; 2008 Dec; 36(12):1704-13. PubMed ID: 18809237
[TBL] [Abstract][Full Text] [Related]
6. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
Schwarz M; Meade G; Stoll P; Ylanne J; Bassler N; Chen YC; Hagemeyer CE; Ahrens I; Moran N; Kenny D; Fitzgerald D; Bode C; Peter K
Circ Res; 2006 Jul; 99(1):25-33. PubMed ID: 16778135
[TBL] [Abstract][Full Text] [Related]
7. TULA-2 (T-Cell Ubiquitin Ligand-2) Inhibits the Platelet Fc Receptor for IgG IIA (FcγRIIA) Signaling Pathway and Heparin-Induced Thrombocytopenia in Mice.
Zhou Y; Abraham S; Renna S; Edelstein LC; Dangelmaier CA; Tsygankov AY; Kunapuli SP; Bray PF; McKenzie SE
Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2315-2323. PubMed ID: 27765766
[TBL] [Abstract][Full Text] [Related]
8. First description of an IgM monoclonal antibody causing α
Pillois X; Guy A; Choquet É; James C; Tuffigo M; Viallard JF; Garcia C; Bordet JC; Jandrot-Perrus M; Payrastre B; Fiore M
J Thromb Haemost; 2019 May; 17(5):795-802. PubMed ID: 30868743
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
[TBL] [Abstract][Full Text] [Related]
10. Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist.
Blue R; Kowalska MA; Hirsch J; Murcia M; Janczak CA; Harrington A; Jirouskova M; Li J; Fuentes R; Thornton MA; Filizola M; Poncz M; Coller BS
Blood; 2009 Jul; 114(1):195-201. PubMed ID: 19414864
[TBL] [Abstract][Full Text] [Related]
11. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet.
Chang CH; Chung CH; Tu YS; Tsai CC; Hsu CC; Peng HC; Tseng YJ; Huang TF
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1307-1314. PubMed ID: 28596377
[TBL] [Abstract][Full Text] [Related]
12. Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis.
Arman M; Krauel K
J Thromb Haemost; 2015 Jun; 13(6):893-908. PubMed ID: 25900780
[TBL] [Abstract][Full Text] [Related]
13. RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarction.
Li J; Vootukuri S; Shang Y; Negri A; Jiang JK; Nedelman M; Diacovo TG; Filizola M; Thomas CJ; Coller BS
Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2321-9. PubMed ID: 25147334
[TBL] [Abstract][Full Text] [Related]
14. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.
Branchford BR; Stalker TJ; Law L; Acevedo G; Sather S; Brzezinski C; Wilson KM; Minson K; Lee-Sherick AB; Davizon-Castillo P; Ng C; Zhang W; Neeves KB; Lentz SR; Wang X; Frye SV; Shelton Earp H; DeRyckere D; Brass LF; Graham DK; Di Paola JA
J Thromb Haemost; 2018 Feb; 16(2):352-363. PubMed ID: 29045015
[TBL] [Abstract][Full Text] [Related]
15. Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin.
Bougie DW; Rasmussen M; Zhu J; Aster RH
Blood; 2012 Jun; 119(26):6317-25. PubMed ID: 22490676
[TBL] [Abstract][Full Text] [Related]
16. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists.
Bassler N; Loeffler C; Mangin P; Yuan Y; Schwarz M; Hagemeyer CE; Eisenhardt SU; Ahrens I; Bode C; Jackson SP; Peter K
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):e9-15. PubMed ID: 17170374
[TBL] [Abstract][Full Text] [Related]
17. Identification of FcgammaRIIa as the ITAM-bearing receptor mediating alphaIIbbeta3 outside-in integrin signaling in human platelets.
Boylan B; Gao C; Rathore V; Gill JC; Newman DK; Newman PJ
Blood; 2008 Oct; 112(7):2780-6. PubMed ID: 18641368
[TBL] [Abstract][Full Text] [Related]
18. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
Leclerc JR
Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
[TBL] [Abstract][Full Text] [Related]
19. Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61).
Schwarz M; Katagiri Y; Kotani M; Bassler N; Loeffler C; Bode C; Peter K
J Pharmacol Exp Ther; 2004 Mar; 308(3):1002-11. PubMed ID: 14617694
[TBL] [Abstract][Full Text] [Related]
20. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.
Bougie DW; Wilker PR; Wuitschick ED; Curtis BR; Malik M; Levine S; Lind RN; Pereira J; Aster RH
Blood; 2002 Sep; 100(6):2071-6. PubMed ID: 12200368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
